Horizon Kinetics’s Celldex Therapeutics CLDX Stock Holding History

Horizon Kinetics’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$5K	Hold	1,756	–	–	﹤0.01%	473
2018 Q3	$12K	Hold	1,756	–	–	﹤0.01%	502
2018 Q2	$13K	Hold	1,756	–	–	﹤0.01%	509
2018 Q1	$61K	Hold	1,756	–	–	﹤0.01%	496
2017 Q4	$75K	Hold	1,756	–	–	﹤0.01%	488
2017 Q3	$75K	Hold	1,756	–	–	﹤0.01%	485
2017 Q2	$65K	Hold	1,756	–	–	﹤0.01%	500
2017 Q1	$95K	Hold	1,756	–	–	﹤0.01%	491
2016 Q4	$93K	Hold	1,756	–	–	﹤0.01%	494
2016 Q3	$106K	Hold	1,756	–	–	﹤0.01%	495
2016 Q2	$115K	Hold	1,756	–	–	﹤0.01%	505
2016 Q1	$99K	Hold	1,756	–	–	﹤0.01%	512
2015 Q4	$413K	Hold	1,756	–	–	0.01%	413
2015 Q3	$277K	Hold	1,756	–	–	0.01%	439
2015 Q2	$664K	Hold	1,756	–	–	0.01%	378
2015 Q1	$734K	Hold	1,756	–	–	0.01%	376
2014 Q4	$481K	Hold	1,756	–	–	0.01%	414
2014 Q3	$341K	Hold	1,756	–	–	﹤0.01%	445
2014 Q2	$430K	Hold	1,756	–	–	0.01%	438
2014 Q1	$465K	Hold	1,756	–	–	0.01%	419
2013 Q4	$638K	Hold	1,756	–	–	0.01%	297
2013 Q3	$933K	Buy	1,756 +3	+0.2%	+$1.03K	0.01%	249
2013 Q2	$410K	Buy	+1,753	New	+$345K	0.01%	339

Other funds holding CLDX

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Horizon Kinetics's CLDX Position: Q4 2018 in Review

Horizon Kinetics held its Celldex Therapeutics (CLDX) position steady in Q4 2018 at 1,756 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #473.

Horizon Kinetics first reported a position in CLDX in Q2 2013 and has held it in 23 quarters since. The position peaked at $933K in Q3 2013. 85 funds tracked by Wall St. Rank hold CLDX as of Q4 2018.

Horizon Kinetics held 1,756 shares of Celldex Therapeutics worth $5K as of Q4 2018.
Horizon Kinetics left its Celldex Therapeutics share count unchanged in Q4 2018.
Celldex Therapeutics made up ﹤0.01% of Horizon Kinetics's portfolio in Q4 2018, its #473 holding.
Horizon Kinetics first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 23 quarters since.
Horizon Kinetics's Celldex Therapeutics position peaked at $933K in Q3 2013.
85 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2018.

Based on Horizon Kinetics's 13F filing for Q4 2018, filed 14 Feb 2019.